AlphaCentric Advisors’s Globus Medical GMED Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$749K Hold
10,000
– – 0.67% 37
2026
Q2
$790K Buy
10,000
+2,500
+33% +$212K 0.67% 40
2026
Q1
$646K Sell
7,500
-1,212
-14% -$109K 0.65% 43
2025
Q4
$761K Buy
+8,712
New +$661K 0.76% 35
2024
Q4
$2M Buy
+24,176
New +$1.91M 2% 10
2024
Q2
– Sell
-12,500
Closed -$670K – 235
2024
Q1
$670K Buy
+12,500
New +$672K 0.4% 77
2023
Q4
– Sell
-10,000
Closed -$496K – 253
2023
Q3
$496K Buy
+10,000
New +$559K 0.28% 88
2023
Q1
– Sell
-10,000
Closed -$743K – 214
2022
Q4
$743K Buy
10,000
+9,000
+900% +$613K 0.73% 49
2022
Q3
$60K Buy
+1,000
New +$60.2K 0.06% 169
2021
Q1
– Sell
-15,000
Closed -$978K – 213
2020
Q4
$978K Hold
15,000
– – 0.41% 17
2020
Q3
$743K Hold
15,000
– – 0.36% 22
2020
Q2
$716K Buy
+15,000
New +$724K 0.4% 21

Other funds holding GMED

AlphaCentric Advisors's GMED Position: Q3 2026 in Review

AlphaCentric Advisors held its Globus Medical (GMED) position steady in Q3 2026 at 10,000 shares worth $749K. The position accounts for 0.67% of the portfolio, ranked #37.

AlphaCentric Advisors first reported a position in GMED in Q2 2020 and has held it in 12 quarters since. The position peaked at $2M in Q4 2024. 617 funds tracked by Wall St. Rank hold GMED as of Q3 2026.

  • AlphaCentric Advisors held 10,000 shares of Globus Medical worth $749K as of Q3 2026.
  • AlphaCentric Advisors left its Globus Medical share count unchanged in Q3 2026.
  • Globus Medical made up 0.67% of AlphaCentric Advisors's portfolio in Q3 2026, its #37 holding.
  • AlphaCentric Advisors first reported a position in Globus Medical in Q2 2020 and has held it in 12 quarters since.
  • AlphaCentric Advisors's Globus Medical position peaked at $2M in Q4 2024.
  • 617 funds tracked by Wall St. Rank held Globus Medical as of Q3 2026.

Based on AlphaCentric Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.